Overview

Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection

Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
Phase:
Phase 4
Details
Lead Sponsor:
Shandong University
Treatments:
Amoxicillin
Esomeprazole
Furazolidone
Rabeprazole
Tetracycline